Mediators involved in the cancer anorexia-cachexia syndrome:: past, present, and future

被引:71
|
作者
Argilés, JM [1 ]
Busquets, S [1 ]
García-Martínez, C [1 ]
López-Soriano, FJ [1 ]
机构
[1] Univ Barcelona, Canc Res Grp, Dept Bioquim & Biol Mol, Fac Biol, Barcelona, Spain
关键词
cytokines; transcriptional factors; therapeutical strategies;
D O I
10.1016/j.nut.2005.02.003
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The cachectic syndrome, characterized by a marked weight loss, anorexia, asthenia, and anemia is invariably associated with the presence and growth of the tumor and leads to a malnutrition status due to the induction of anorexia or decreased food-intake. In addition, the competition for nutrients between the tumor and the host leads to an accelerated starvation state, which promotes severe metabolic disturbances in the host, including hypermetabolism, which leads to an increased energetic inefficiency. Although the search for the cachectic factor(s) started a long time ago, and although many scientific and economic efforts have been devoted to its discovery, we are still a long way from knowing the whole truth. Present investigation is devoted to revealing the different signaling pathways, in particular transcriptional factors involved in muscle wasting. The main aim of the present review is to summarize and evaluate the different molecular mechanisms and catabolic mediators (both Immoral and tumoral) involved in cancer cachexia since they may represent targets for future promising clinical investigations. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [31] Megestrol acetate for the treatment of anorexia-cachexia syndrome
    Berenstein, EG
    Ortiz, Z
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [32] Megestrol acetate for treatment of anorexia-cachexia syndrome
    Ruiz Garcia, Vicente
    Lopez-Briz, Eduardo
    Carbonell Sanchis, Rafael
    Gonzalvez Perales, Jose Luis
    Bort-Marti, Sylvia
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (03):
  • [33] Anorexia-Cachexia Syndrome in Pancreatic Cancer: Recent Development in Research and Management
    Uomo, Generoso
    Gallucci, Fernando
    Rabitti, Pier Giorgio
    JOURNAL OF THE PANCREAS, 2006, 7 (02): : 157 - 162
  • [34] Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway
    Camps, Carlos
    Iranzo, Vega
    Bremnes, Roy M.
    Sirera, Rafael
    SUPPORTIVE CARE IN CANCER, 2006, 14 (12) : 1173 - 1183
  • [35] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins
    PHARMACY WORLD & SCIENCE, 2007, 29 (03): : 288 - 289
  • [36] Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
    Yu Bai
    Yunxia Hu
    Yanhua Zhao
    Xizhong Yu
    Junwei Xu
    Zhiyun Hua
    Zhiqiang Zhao
    Supportive Care in Cancer, 2017, 25 : 1651 - 1659
  • [37] Primary tumorous anorexia-cachexia syndrome and forms of intervention
    Jarisch, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 737 - 737
  • [38] Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome
    Fujitsuka, Naoki
    Uezono, Yasuhito
    FRONTIERS IN PHARMACOLOGY, 2014, 5
  • [39] A New Horizon of Herbal Medicines in Anorexia-Cachexia Syndrome
    Inui, Akio
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (31) : 4747 - 4748
  • [40] Audit of symptoms and prescribing in patients with the anorexia-cachexia syndrome
    Andrew, Inga
    Kirkpatrick, Graeme
    Holden, Keith
    Hawkins, Colette
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 489 - 496